[go: up one dir, main page]

MXPA04011612A - Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo. - Google Patents

Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.

Info

Publication number
MXPA04011612A
MXPA04011612A MXPA04011612A MXPA04011612A MXPA04011612A MX PA04011612 A MXPA04011612 A MX PA04011612A MX PA04011612 A MXPA04011612 A MX PA04011612A MX PA04011612 A MXPA04011612 A MX PA04011612A MX PA04011612 A MXPA04011612 A MX PA04011612A
Authority
MX
Mexico
Prior art keywords
roflumilast
eye
treatment
diseases
ophthalmological use
Prior art date
Application number
MXPA04011612A
Other languages
English (en)
Inventor
Koenen Rudiger
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of MXPA04011612A publication Critical patent/MXPA04011612A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F41B5/123—Compound crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/14—Details of bows; Accessories for arc shooting
    • F41B5/1442—Accessories for arc or bow shooting
    • F41B5/1469—Bow-string drawing or releasing devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una preparacion farmaceutica que comprende roflumilasto para el tratamiento de una enfermedad del ojo.
MXPA04011612A 2002-05-28 2003-05-27 Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo. MXPA04011612A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02011830 2002-05-28
DE10223828 2002-05-28
DE10311613 2003-03-14
PCT/EP2003/005536 WO2003099278A1 (en) 2002-05-28 2003-05-27 Ophthalmological use of roflumilast for the treatment of diseases of the eye

Publications (1)

Publication Number Publication Date
MXPA04011612A true MXPA04011612A (es) 2005-03-07

Family

ID=29587313

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04011528A MXPA04011528A (es) 2002-05-28 2003-05-27 Preparacion farmaceutica que se puede aplicar por via topica.
MXPA04011612A MXPA04011612A (es) 2002-05-28 2003-05-27 Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA04011528A MXPA04011528A (es) 2002-05-28 2003-05-27 Preparacion farmaceutica que se puede aplicar por via topica.

Country Status (32)

Country Link
US (7) US20060084685A1 (es)
EP (3) EP2020243B1 (es)
JP (3) JP2005529928A (es)
KR (2) KR20050014844A (es)
CN (3) CN1655823B (es)
AT (2) ATE417628T1 (es)
AU (2) AU2003240719B2 (es)
BR (2) BR0311337A (es)
CA (2) CA2486910C (es)
CY (2) CY1110312T1 (es)
DE (2) DE60325354D1 (es)
DK (3) DK1511481T3 (es)
EA (2) EA020569B1 (es)
ES (3) ES2319517T3 (es)
HR (1) HRP20041211B1 (es)
HU (1) HUE039709T2 (es)
IL (3) IL164935A (es)
IS (1) IS2639B (es)
LT (1) LT2020243T (es)
MA (1) MA27813A1 (es)
ME (1) ME00565A (es)
MX (2) MXPA04011528A (es)
NO (2) NO334882B1 (es)
NZ (3) NZ553731A (es)
PL (3) PL397021A1 (es)
PT (3) PT2020243T (es)
RS (1) RS51104B (es)
SI (2) SI2020243T1 (es)
TR (1) TR201815573T4 (es)
UA (2) UA81910C2 (es)
WO (2) WO2003099278A1 (es)
ZA (2) ZA200408649B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PT2020243T (pt) * 2002-05-28 2018-11-09 Astrazeneca Ab Preparação farmacêutica para uso tópico
MXPA05003063A (es) 2002-09-20 2005-05-27 Alcon Inc Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos.
FR2851247B1 (fr) * 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
AU2004220357B2 (en) 2003-03-10 2010-09-30 Astrazeneca Ab Novel process for the preparation of roflumilast
CA2552524A1 (en) * 2004-01-10 2005-07-28 Biolipid, Inc. Lipid compositions and methods of use
DE102004046236A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
NZ560269A (en) 2005-03-08 2010-12-24 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
CN101193634A (zh) * 2005-06-09 2008-06-04 参天制药株式会社 罗氟司特滴眼液
US7939540B2 (en) 2006-02-21 2011-05-10 Eisai R&D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives
WO2008099887A1 (ja) 2007-02-16 2008-08-21 Eisai R & D Management Co., Ltd. メチル ｎ－［３－（６，７－ジメトキシ－２－メチルアミノキナゾリン－４－イル）フェニル］テレフタラミックアシッドの結晶、非晶質体または塩
CA2696793A1 (en) 2007-08-17 2009-02-26 Eisai R&D Management Co., Ltd. Novel preparation for external use
JP5043945B2 (ja) 2007-08-17 2012-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナゾリン誘導体の製造方法
MX2012004777A (es) 2009-10-30 2012-06-01 Nestec Sa Metodos para mantener la salud de los ojos y mejorar enfermedades oftalmicas en caninos.
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
ES2408132B1 (es) * 2010-09-08 2014-04-04 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento de la epífora.
ES2711100T3 (es) 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
CN102793684B (zh) * 2011-05-26 2016-02-17 杭州赛利药物研究所有限公司 罗氟司特液体制剂及其制备方法
WO2013000917A1 (en) * 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing regorafenib
WO2013155123A1 (en) * 2012-04-10 2013-10-17 Georgia State University Research Foundation, Inc. Compositions and methods for treating otitis media and other conditions with inhibitors of cyld
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
WO2014072937A1 (en) 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
CN105434328A (zh) * 2014-09-01 2016-03-30 天津药物研究院有限公司 一种含罗氟司特固体分散体的固体制剂及其制备方法
KR101878621B1 (ko) * 2014-10-24 2018-07-13 히사미쓰 세이야꾸 가부시키가이샤 프로드러그
CN104997959A (zh) * 2015-08-21 2015-10-28 蔡宇平 一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) * 2016-07-11 2019-10-01 赵晨 一种遗传性Usher综合征的致病突变及其检测试剂
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) * 2018-03-13 2018-07-17 兆科药业（广州）有限公司 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
BR112020024768A8 (pt) * 2018-06-04 2022-12-13 Arcutis Inc Método para reduzir o intervalo de penetração cutânea de roflumilaste em um paciente, composição farmacêutica compreendendo roflumilaste e uma mistura emulsificante e composição farmacêutica compreendendo roflumilaste e pelo menos um emulsificante
KR102117525B1 (ko) * 2018-07-09 2020-06-01 건양대학교 산학협력단 Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
BR112022015104A2 (pt) * 2020-01-31 2022-09-27 Arcutis Biotherapeutics Inc Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição
KR20220074935A (ko) * 2020-05-07 2022-06-03 아큐티스 바이오테라퓨틱스, 인크. 높은 크라프트 온도 음이온성 계면활성제를 이용한 피부병의 치료
AU2021393513A1 (en) 2020-12-04 2023-07-06 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
JP2024506384A (ja) 2021-02-10 2024-02-13 イオリクス セラピューティクス，インコーポレーテッド ロフルミラストの眼科的送達方法
MX2023014380A (es) * 2021-06-01 2024-03-04 Eyedea Bio Llc Sistema de administracion de medicamentos de liberacion prolongada para medicamentos oculares y metodos de uso.
IL311534A (en) 2021-09-22 2024-05-01 Iolyx Therapeutics Inc Methods of treating ocular inflammatory diseases
CN118076340A (zh) 2021-12-17 2024-05-24 爱瑞制药公司 眼用药物组合物及其用途
AU2023342481A1 (en) 2022-09-15 2025-04-10 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
WO2025054483A1 (en) 2023-09-07 2025-03-13 Arcutis Biotherapeutics, Inc. Dosing regimens using topical roflumilast compositions
US20250090509A1 (en) * 2023-09-15 2025-03-20 Arcutis Biotherapeutics, Inc. Methods of reducing itch using topical roflumilast compositions
WO2025080415A1 (en) 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
CN117462487A (zh) * 2023-11-29 2024-01-30 沈阳药科大学 一种罗氟司特油凝胶及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) * 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
CN1046939C (zh) * 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
CN1128955A (zh) * 1993-08-10 1996-08-14 藤泽药品工业株式会社 经皮吸收制剂
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
EP1118615A4 (en) * 1998-09-29 2002-02-27 Fujisawa Pharmaceutical Co PYRIDOPYRAZINE DERIVATIVES SALTS AND CRYSTALS THEREOF
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
DE60015098T2 (de) 1999-03-10 2006-02-02 Altana Pharma Ag 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
EA200200502A1 (ru) * 1999-10-29 2002-10-31 Смитклайн Бичам Корпорейшн Способ введения ингибитора фосфодиэстеразы 4
EA005028B1 (ru) * 2000-01-31 2004-10-28 Пфайзер Продактс Инк. Пиримидинкарбоксамиды, используемые в качестве ингибиторов изозимов pde4
EP1261331A4 (en) * 2000-02-16 2005-01-05 Univ Nebraska Medical Ct METHOD AND COMPOSITIONS FOR TREATING FIBROSANT DISEASES
JP2003534328A (ja) * 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
AU2002227123A1 (en) * 2000-11-07 2002-05-21 Merck And Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) * 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
PT2020243T (pt) * 2002-05-28 2018-11-09 Astrazeneca Ab Preparação farmacêutica para uso tópico

Also Published As

Publication number Publication date
US20110313005A1 (en) 2011-12-22
NZ537308A (en) 2009-09-25
DK2020243T3 (en) 2018-11-19
PT1511516E (pt) 2009-02-20
DK1511516T3 (da) 2009-04-06
CY1121133T1 (el) 2019-12-11
AU2003232828B2 (en) 2010-06-24
ZA200408649B (en) 2007-12-27
IL164935A0 (en) 2005-12-18
JP5652983B2 (ja) 2015-01-14
JP2005529928A (ja) 2005-10-06
HRP20041211B1 (hr) 2013-06-30
JP2012229245A (ja) 2012-11-22
IS2639B (is) 2010-06-15
ZA200409584B (en) 2006-05-31
ME00565A (en) 2011-12-20
CA2486917C (en) 2011-11-22
AU2003240719B2 (en) 2009-12-10
EA200702588A1 (ru) 2008-08-29
PL211870B1 (pl) 2012-07-31
UA81910C2 (uk) 2008-02-25
PL397021A1 (pl) 2012-03-26
EP1511516A1 (en) 2005-03-09
JP5683538B2 (ja) 2015-03-11
CN101491520B (zh) 2011-03-16
EA020569B1 (ru) 2014-12-30
DK1511481T3 (da) 2011-01-24
NO20045656L (no) 2004-12-27
EP1511481A1 (en) 2005-03-09
SI2020243T1 (sl) 2018-11-30
DE60334692D1 (de) 2010-12-09
HK1079437A1 (en) 2006-04-07
US20060084684A1 (en) 2006-04-20
NZ536920A (en) 2007-04-27
UA88523C2 (ru) 2009-10-26
IL164935A (en) 2010-12-30
IS7612A (is) 2004-12-23
MXPA04011528A (es) 2005-02-14
KR20050014844A (ko) 2005-02-07
NO334882B1 (no) 2014-06-30
DE60325354D1 (de) 2009-01-29
PL212134B1 (pl) 2012-08-31
CA2486910A1 (en) 2003-12-04
US20080280958A1 (en) 2008-11-13
CN100490804C (zh) 2009-05-27
KR20110122230A (ko) 2011-11-09
ES2693094T3 (es) 2018-12-07
ATE417628T1 (de) 2009-01-15
RS51104B (sr) 2010-10-31
ES2319517T3 (es) 2009-05-08
CN1655823B (zh) 2010-05-26
US20210116207A1 (en) 2021-04-22
RS101404A (en) 2007-02-05
CY1110312T1 (el) 2015-01-14
ATE485821T1 (de) 2010-11-15
EA010416B1 (ru) 2008-08-29
CA2486917A1 (en) 2003-12-04
PL372095A1 (en) 2005-07-11
US20190029956A1 (en) 2019-01-31
CN1655823A (zh) 2005-08-17
EP2020243A1 (en) 2009-02-04
WO2003099278A1 (en) 2003-12-04
KR101307093B1 (ko) 2013-09-11
IL209657A0 (en) 2011-02-28
BR0311339A (pt) 2005-03-22
PL372082A1 (en) 2005-07-11
EP1511516B1 (en) 2008-12-17
ES2354971T3 (es) 2011-03-21
WO2003099334A1 (en) 2003-12-04
IL165065A0 (en) 2005-12-18
JP2005529930A (ja) 2005-10-06
AU2003240719A1 (en) 2003-12-12
US20140303215A1 (en) 2014-10-09
PT2020243T (pt) 2018-11-09
CN101491520A (zh) 2009-07-29
CA2486910C (en) 2011-11-29
TR201815573T4 (tr) 2018-11-21
NO20045506L (no) 2004-12-16
EP2020243B1 (en) 2018-08-15
MA27813A1 (fr) 2006-04-03
IL165065A (en) 2010-11-30
PT1511481E (pt) 2011-01-14
HRP20041211A2 (hr) 2006-04-30
BR0311337A (pt) 2005-03-15
SI1511516T1 (sl) 2009-06-30
EA200401517A1 (ru) 2005-06-30
HUE039709T2 (hu) 2019-01-28
HK1079445A1 (zh) 2006-04-07
NZ553731A (en) 2007-07-27
EP1511481B1 (en) 2010-10-27
NO334916B1 (no) 2014-07-14
LT2020243T (lt) 2018-11-12
AU2003232828A1 (en) 2003-12-12
CN1655782A (zh) 2005-08-17
US20060084685A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
GB0211649D0 (en) Organic compounds
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
EP1578421A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
FI9630U1 (fi) Järjestelmä potilaan silmän verkkokalvon hoitamiseksi laserilla
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
MX2007001679A (es) Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
GB0620385D0 (en) Novel compounds
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
WO2005048950A3 (en) Tumor and infectious disease therapeutic compositions
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
TW200501935A (en) Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
AU2002322263A1 (en) Eglin c based drugs for treatment of disease
EA200970562A1 (ru) Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы
AU2002252610A1 (en) Ultrasonic profiling of medicament administration into tissue
AU2003209542A1 (en) Use of s-substituted l-crysteine for the manufacture of a medicament for the treatment of dermatological disorders
NZ542305A (en) Treatment of proliferative diseases with an epothilone derivative and radiation
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren
NO20042586L (no) Behandlingsfremgangsmate
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
HRP20040165A2 (en) Citalopram for the treatment of elevated blood pressure

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration
HC Change of company name or juridical status